Drug Profile
CVI HBV 001
Alternative Names: CVI-HBV-001Latest Information Update: 29 Aug 2019
Price :
$50
*
At a glance
- Originator Cha Vaccine Institute
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Hepatitis B
Most Recent Events
- 29 Aug 2019 CVI HBV 001 is still in phase I/II trials for Hepatitis B (In volunteers, Prevention) in South Korea (IM) (Cha Vaccine Institute website, August 2019)